The threat of Carbapenem-Resistant Enterobacteriaceae

The threat of Carbapenem-Resistant Enterobacteriaceae

CRE infections are becoming a major concern in healthcare settings worldwide.

This family of bacteria is notorious for its resistance to almost all available antibiotics, significantly limiting treatment options. The bacteria’s ability to spread rapidly poses a serious risk, especially when outbreaks occur, adding to both patient suffering and the financial burden on healthcare systems.
The mortality rates linked to CRE infections are also alarming.

In severe cases, the mortality rate can reach 75%. For patients suffering from CRE bloodstream infections, the mortality rate is observed to be around 50%. These statistics underscore the critical nature of these infections and the need for better treatment options and infection control strategies.

In addition, CRE infections place a heavy financial strain on healthcare systems:

🇺🇸 In the United States, the estimated annual healthcare costs associated with CRE infections amount to approximately $130 million.
🇫🇷 In France, over a two-year period, the cost for treating 16 patients carrying carbapenemase-producing CRE reached over €640,000.
🇬🇧 In the United Kingdom, similarly, a CRE outbreak in five hospitals over a span of 10 months led to expenses exceeding €1 million.
 


How to address the growing threat of CRE infections?


 

CRE infections are not only a serious health risk due to their high mortality rates but also pose a significant economic challenge to healthcare systems. As the threat of these antibiotic-resistant bacteria grows, it is imperative to focus on prevention and rapid detection to support easing their impact on both patients and healthcare facilities.


Discover CHROMagar™ mSuperCARBA™


 

CHROMagar™ mSuperCARBA™ is designed for detection and isolation ofCarbapenem-Resistant Enterobacteriaceae (CRE).


Its main advantages are:



  • 🔬 Differentiation of most CRO*:
    Designed to detect a wide range of carbapenemase producers (KPC, NDM, VIM, IMP, OXA…). It can even detect weakly expressed carbapenemases like OXA-244 and OXA-48.



  • 🎯 Highly selective and specific:
    The medium inhibits not only beta-lactam susceptible bacteria but also most ESBL and AmpC hyperproducers.



  • 🔍 Impressive limit of detection:
    It possesses an impressive limit of detection of 10 CFU/ml.



  • ⏲️ Fast results
    Can be interpreted after 18-24h of aerobic incubation at 35-37°C.




You can find here 👈 all the technical documents and information about CHROMagar™ mSuperCARBA™
Here to support you
Do you have any questions or want to have more details? Don't hesitate to contact us here 👈
Our team will delighted to reach out to you in a brief time 💜




The CHROMagar Team


* CRO: Carbapenem-Resistant organism.
1. Carbapenem-resistant Enterobacteriaceae – second update, 26 September 2019, ECDC.
2. CDC, 2019 Antibiotic Resistance Threats Report, Carbapenem-resistant Enterobacteriaceae (CRE) MAR 25/2024. https://www.cdc.gov/antimicrobial-resistance/media/pdfs/cre-508.pdf
3. Daroukh A, Delaunay C, Bigot S, et al. Characteristics and costs of carbapenemase-producing enterobacteria carriers (2012/2013). Med Mal Infect. 2014;44(7):321-326. doi:10. 1016/j.medmal.2014.06.004
4. Otter JA, Burgess P, Davies F, et al. Counting the cost of an outbreak of carbapenemase-producing Enterobacteriaceae: an economic evaluation from a hospital perspective. Clin Microbiol Infect. 2017;23(3):188-196. doi:10.1016/j.cmi.2016.10.005
5. Garcia-Fernandez et al., 2017. Diagn. Micr. Infect. Dis.